It's a controversial arena -- the PSA is a marker of prostate bulk and size, but it's highly expressed in benign prostate disease as well as cancer -- so in that context it's not a specific marker.
Initially, we envision this new test could be used as a supplement to PSA. A physician might suggest a patient with an elevated PSA have this test before a biopsy to better determine whether it's a cancerous or benign condition. In the future, I think this could replace PSA.